Form 4: BioLife Solutions Chief Technology Officer, Sean Werner, Reports Acquisition of Common Stock

Sean Werner, Chief Technology Officer of BioLife Solutions Inc., reports acquiring 22,919 shares of common stock on March 18, 2025, as part of his 2025 compensation.

Summary

• On March 18, 2025, Sean Werner, the Chief Technology Officer of BioLife Solutions Inc., acquired 22,919 shares of common stock.
• This acquisition was part of his 2025 compensation package.
• Following the transaction, Werner directly owns 27,784 shares of BioLife Solutions Inc.
• The restricted stock vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments, pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing about stock acquisition, which doesn't inherently indicate positive or negative sentiment. The acquisition by an officer could be seen as a mild positive.

Positives

• The acquisition of shares by a high-ranking officer like the CTO can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when company insiders, like the Chief Technology Officer, engage in transactions involving the company's securities. It provides transparency to the market regarding insider activity.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a key executive.

Key Dates

Keywords

BioLife Solutions, BLFS, Sean Werner, Chief Technology Officer, Stock Acquisition, Form 4, Insider Trading, Compensation, Restricted Stock, 2023 Omnibus Performance Incentive Plan